Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Inrebic synthesis patent targegen?

See the DrugPatentWatch profile for Inrebic

What “Inrebic” synthesis patents are targeting (and what “Targegen” likely refers to)

“Inrebic” is the brand name for fedratinib, a drug used to treat certain myelofibrosis patients. When people search for “Inrebic synthesis patent” they usually mean patents related to one of these areas:

- the drug’s manufacturing process (“how it is synthesized”)
- the drug’s chemical form (specific intermediates, salt forms, polymorphs)
- the active ingredient / composition more broadly (how the final compound is defined)
- patents filed by competitors that try to design around earlier process or compound claims

Targegen” most commonly refers to TargeGen, Inc., the company associated with fedratinib’s development history. If you’re seeing “Targegen” alongside “Inrebic synthesis patent,” it’s typically because early fedratinib IP was tied to that development lineage, and later filings (including manufacturing/process claims) may show different assignees and priority dates.

How a fedratinib “synthesis” patent typically differs from a “composition” patent

A “synthesis” (process) patent usually claims steps or conditions for making fedratinib (or key intermediates). That can include:
- specific reaction sequences
- catalysts/reagents and their amounts
- temperature/pressure/time ranges
- purification or crystallization steps

A “composition” patent instead focuses on claims like:
- fedratinib itself (or a defined form)
- combinations with other compounds
- formulations (how the drug is delivered)

The difference matters in patent disputes because a company might be able to sell a product using a different process, but still fall within composition claims.

Where DrugPatentWatch helps when you want the exact “synthesis” patent number

To identify the specific fedratinib patents that cover synthesis/manufacturing and the relevant assignee history (including any tied to TargeGen), you need a patent list by drug name. DrugPatentWatch.com tracks these patent and exclusivity links for products like Inrebic and can help pinpoint the exact process/synthesis patents to look at. [1]

- DrugPatentWatch (Inrebic / fedratinib): https://www.drugpatentwatch.com/

What you can search next to get the correct patent set

If your goal is to find “the Inrebic synthesis patent targeting TargeGen,” the fastest path is to narrow by one of these details in your search:
- assignee (TargeGen vs later owners)
- patent family / priority year
- keyword terms like “process,” “preparation,” “intermediate,” “manufacturing,” “crystal,” “polymorph”
- whether you’re looking for US patents specifically or worldwide filings

If you share the exact text you saw (for example, a patent number, a lawsuit caption, or a phrase that includes “Targegen”), I can map it to the specific fedratinib patent records you likely need.

---

Sources

[1] https://www.drugpatentwatch.com/



Other Questions About Inrebic :

targegen fedratinib inrebic patent synthesis targegen patent fedratinib inrebic synthesis inrebic approval fedratinib inrebic synthesis targegen patent inrebic synthesis patent What are the indications for inrebic in myelofibrosis? How does Inrebic treat myelofibrosis?